

Mental Health Quality Advisory Committee Meeting

July 16, 2009

+++**DRAFT MEMORANDA**+++

Committee Members: P- Present, A- Absent

James Koontz	P	Dr. George Parker	P	Pat Casanova	A
Stephen McCaffrey	P	Jeremy Thain	P	Katherine Wentworth	P
Carol Ott	P				

In attendance representing the FSSA/OMPP:

Marc Shirley, Medina Lee, Kristin Johnson

Opening Comments

Ms. Casanova was unable to attend the July meeting. Stephen McCaffrey was asked to chair the meeting in her absence. Mr. McCaffrey said that a representative from the Department of Corrections will be added as a member to the Committee.

Approval of Minutes

Motion: A motion to approve the draft memoranda of the April 16, 2009 meeting as written was moved, seconded, and approved unanimously.

Utilization Edits

Dr. Carol Ott provided a list of the *MHQAC Quarterly Review of Utilization Edits, 2nd Quarter 2009* which listed the medications and the proposed utilization edits.

Motion: A motion to approve the edits was moved, seconded, and approved unanimously.

SmartPA Implementation Status Update

Marc Shirley, of the Office of Medicaid Policy and Planning (OMPP), said the expected date for the implementation of the SmartPA is scheduled for October 1, 2009. Mr. Shirley said that if the six proposals are approved by the MHQAC, they will be presented to the DUR Board at their August meeting.

SmartPA Clinical Edit Proposals

Mr. John Stancil of ACS introduced two Richmond clinical pharmacist colleagues, Karen Powell and Doug Brink, both of whom participated by conference call with Mr. Stancil for a presentation of the SmartPA Proposals. Mr. Stancil's presentation consisted of the approval and denial criteria for the following:

1. Atypical Antipsychotics Duplicate Therapy
2. SSRIs and SNRIs Duplicate Therapy
3. Sedative/Hypnotics Duplicate Therapy
4. Stimulants Duplicate Therapy
5. Typical Antipsychotics Duplicate Therapy
6. Low Dose Atypical Antipsychotic Therapy

Motion: the following was agreed upon for each SmartPA Clinical Edit Proposal:

Atypical Antipsychotics

- The approval criteria for the history should be 2 weeks instead of 8 weeks of a single-drug therapy at an adequate dose.
- The check for the prescriber being a psychiatrist should be moved up to the first check after duplicative therapy is established.
- Psychiatrists should be exempt from the Black Box warning check. The Office can determine if other prescribers should also be exempt.
- The Black Box warning check should include all patients \geq 65 years old, not just those with a diagnosis of dementia.
- Subsequent prior authorizations to the 6 month approval should be for 12 months if no changes.
- The minimum effective dose for paliperidone should be changed from \geq 6 mg/day to \geq 3mg/day.

SSRI's and SNRI's

- The approval criteria for the history should be 4 weeks instead of 8 weeks of a single-drug therapy at an adequate dose.
- Subsequent prior authorizations to the 6 month approval should be for 12 months if no changes.

Mental Health Quality Advisory Committee Meeting

July 16, 2009

+++**DRAFT MEMORANDA**+++

Sedative/Hypnotics

- Remove the approval criteria check of history of at least 8 weeks of single-drug therapy at an adequate dose of each medication.
- Add all benzodiazepines to the rule except clonazepam.
- Allow concomitant use of trazodone and an antianxiety benzodiazepine.
- Do not allow trazodone concomitant use with a sedative/hypnotic.
- Add call center question, "Has the sedative/hypnotic or benzo in history been discontinued?"

Stimulants Duplicative Therapy

- The approval criteria for the history should be 2 weeks instead of 8 weeks of a single-drug therapy at an adequate dose.

Typical Antipsychotics Duplicate Therapy

- The approval criteria for the history should be 2 weeks instead of 8 weeks of a single-drug therapy at an adequate dose.
- Subsequent prior authorizations to the 6 month approval should be for 12 months if no changes.

Low Dose Atypical Antipsychotic Therapy

- The minimum effective dose for paliperidone should be changed from ≥ 6 mg/day to ≥ 3 mg/day.
- The minimum effective dose for aripiprazole should be changed from ≥ 10 mg/day to ≥ 5 mg/day.

April 25, 2009 Symposium

Dr. John Wernert was not available to provide an update at this time. The MHQAC members who attended the symposium agreed they were impressed and look forward to possible future symposiums.

E-mail Received at MHQAC E-mail Address

It was noted that no e-mails had been received in the MHQAC's dedicated e-mail account.

Pilot Programs Status

Dr. Wernert was not available to provide an update at this time.

Old Business

There is nothing to report on at this time.

New Business

None

Agenda items for the next meeting

- DUR Updates
- Utilization edits
- Implementation of SmartPA
- PA stats for October
- Debrief of Symposium – John Wernert
- Update on pilot programs – John Wernert
- E-mail received at MHQAC e-mail address
- Standing agenda items

Meeting adjourned at 12:01 P.M.

The next meeting will be October 15, 2009 at 10:00 A.M. EST in Conference Center Room "A" of the Indiana Government Center South Building.